静脈ステント市場：市場規模（セグメント別）、シェア、規制、償還、手技、予測（～2033年）

慢性静脈疾患（CVD）または慢性静脈不全（CVI）は、発展途上国および先進国における世界の負担として浮上しています。これは、下肢の静脈壁や弁が効率的に機能せず、血液が下肢から心臓に戻るのがますます困難になる状態を指します。

深部静脈血栓症（DVT）は、身体の太い深部静脈に血栓が形成される、生命を脅かす可能性のある疾患です。DVTの多くは腸骨大腿静脈の近位または遠位、骨盤部に起こります。DVTは体の他の部位に起こることもあります。深部静脈血栓症（DVT）は急性/亜急性および慢性に分類されます。重大な狭窄や外因性圧迫がある場合には、静脈ステントの留置が考慮されます。

当レポートは、世界の静脈ステント市場について詳細に考察し、市場における競合情勢、SWOT分析、2033年までの市場予測、COVID-19の影響、地域、国別の動向などを提供しています。

目次

現在上市されている静脈ステントと競合情勢

• 主要な業界動向の洞察
• 静脈ステントのセグメント別総市場収益と2015年～2033年の市場展望
• セグメント別の手技総数、個数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

• 静脈ステント市場のSWOT分析
• 静脈ステント市場に関する競合力学の洞察と動向
• 国別の医療制度の概要
• 国別の償還政策
• 国別の医療技術に関する規制の状況

List of Tables

Not Applicable

List of Figures

Not Applicable

Abstract

Venous Stents Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033 is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.

The model discusses in detail the impact of COVID-19 on Venous Stents market for the year 2020 and beyond. Chronic Venous Disease (CVD) or Chronic venous insufficiency (CVI) has emerged as a global burden on developing and developed countries. It refers to the condition where venous walls and/or valves in the leg are not working efficiently and becomes increasingly difficult for blood to return to the heart from the legs.

Deep Vein Thrombosis (DVT) is a potential life threating condition where a blood clot is formed in the large deep veins in the body. Most of the DVT occurs proximal or distal to iliofemoral vein as well as in the pelvic area. They also can occur in other parts of the body. Deep Vein Thrombosis (DVT) can be characterized into acute/subacute and chronic. Venous stent placement is considered in case of significant stenosis or extrinsic compression.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Venous Stents market and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total Venous Stents market revenue by segment and market outlooks from 2015-2033.
• Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Venous Stents market.
• Competitive dynamics insights and trends provided Venous Stents market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Boston Scientific Corp, Becton Dickinson and Co, Cook Group Inc, Medtronic Plc, OptiMed Medizinische Instrumente GmbH, Plus Medica GmbH.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Venous Stents marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Venous Stents market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Venous Stents market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Venous Stents market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Venous Stents market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Not Applicable